Bluewater Bio’s new growth strategy takes shape

Bluewater Bio has appointed a new chief financial officer in an effort to drive the next phase of growth at the company. Dynshaw Italia will be charged with overseeing potential transactions to broaden the company’s offering beyond its existing HYBACS wastewater treatment technology.

In contrast to Bluewater Bio’s entirely organic growth to date, mergers or acquisitions are now being explored as possible avenues for accelerating growth. “We would be looking at technologies that could further enhance the performance and economics of HYBACS,” CEO Daniel Ishag told GWI. Ishag emphasised that Bluewater Bio will remain a technology company with a focus on wastewater. Disinfection, clarification or aeration technology providers are therefore among the potentially attractive targets. Opportunities in other arenas such as desalination are also a possibility. Bluewater’s European heritage makes the continent the primary area for potential targets.

The company is considering further fundraising to fuel future growth.